Phases of Clinical Trials

notion image

Licensing Authority:

  • USA: FDA
  • India: DCGI (Drug Controller General of India)
notion image
Phase
Participants
Key Objectives
Study Design
Preclinical
In animals
• Pre-clinical study CPCSEA approval
Clinic (Preclini) for Animals in Sea (CPCSEA)
Phase 0
10–15 healthy volunteers
• Use Radiolabeled substances
• [
Pharmacokinetics/ Pharmacodynamics]
"Micro-dosing study."
For Expensive/ toxic drugs
• [Conducted on humans]
micrO, radiO, tOxic drugs = 0
• Exploratory

Maximum drug amount:
100 mcg or (1/100)th of Human Equivalent Dose, whichever is lower.
Phase I
Healthy volunteers
Determine
Maximum Tolerated Dose (MTD)
Toxicity
NOT Efficacy
• Safety
• Tolerability
I → T → Toxicity, Tolerability, safeTy, mTd
Phase II
Patients

100–300 patients
First test of efficacy
• Safety,
Dose range refinement
Single blind studies
Max failure
Phase III
Patients
(up to 5000)
Confirm efficacy = Efficacy trial
Compare safety and efficacy
with old standard or placebo drug
• Multicentric
Double blind studies
Phase IV
Post-market patients
• Identify rare and long-term adverse effects
Post-marketing studies
Blackbox warnings
Phase V
Pharmaco-epidemiology
  • Preclinical study
    • CPSEA approval
    • Clinic (Preclini) for Animals in Sea (CPCSEA)
  • Phase 0
    • IND application filing
      • Submit new experimental drug application to CDSCO
      • for a human clinical trial.
      • 0 = IND (0 discovered by India)
  • Phase 2
    • Central Drugs Standard Control Organisation (CDSCO)
  • After Phase 3
    • NDA filing (3 letter = Phase 3)
    • leading to the drug entering the market.
  • Blackbox warnings
    • Anti depressants = Suicidal effect
      • No Suicide risk → Clozapine & Lithium
    • Monteleukast = Depression & Suicide